echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > AP&T: Efficacy and safety analysis of methotrexate monotherapy in patients with refractory Crohn's disease

    AP&T: Efficacy and safety analysis of methotrexate monotherapy in patients with refractory Crohn's disease

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Crohn's disease (CD) is a chronic recurrent gastrointestinal inflammatory disease with unknown pathogenesis.


    Crohn's disease (CD) is a chronic recurrent gastrointestinal inflammatory disease with unknown pathogenesis.


    Methotrexate (MTX), as an anti-inflammatory drug, was first reported to be used for the treatment of psoriasis, and then it was reported that it could reduce the use of hormones in patients with rheumatoid arthritis.


     

    This study is a retrospective, observational multi-center study.


     

    This study collected data on 110 patients with Crohn's disease who were treated with methotrexate.


     

    This study confirms that monotherapy with methotrexate may be an effective option for patients with Crohn's disease who have previously failed anti-TNFα.


    This study confirms that monotherapy with methotrexate may be an effective option for patients with Crohn's disease who have previously failed anti-TNFα.


     

    Original source:

    Francisco Mesonero.


    wiley.
    com/doi/10.
    1111/apt.
    16315" target="_blank" rel="noopener">Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-α: results from the ENEIDA registry.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.